Received Jul 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
No additional AE/PQC reported; HCP calling to report an AE regarding the RECOMBIVAX HB vaccine. HCP reported that a female patient received the first two doses of the REOCMBIVAX HB vaccines on 09/05/2024 and 11/07/2024 respectively. HCP stated that the patient has not received her; This spontaneous report was received from a pharmacist and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 05-Sep-2024, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), dose number 1, (lot # and expiration date were not reported). On 07-Nov-2024, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), dose number 2, (lot # and expiration date were not reported), both for prophylaxis (inappropriate schedule of product administration). Also, the patient has not received her third dose of the vaccine. No additional adverse event was reported (no adverse event).